1Paul G, Bart Barlogie, James Berenson, et al. Extended follow-up of a phase Ⅱ trial in relapsed, refractory multiple myeloma[J].Cancer,2006,106(6):1316-1319. 被引量：1
2Antonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma[J]. Blood, 2007,109(7):2767-2772. 被引量：1
3Zangari M, Barlogie B, Thertulien R, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival[J]. Chin Lymphoma, 2003,4 (1):32-35. 被引量：1
5Fanucchi M P, Fossella F V, Belt R, et al. Randomized phase Ⅱ study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer [J]. J Clin Oncol,2006,24(31) :5025-5033. 被引量：1
6Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia[J]. Cancer, 2007,109(11):2285-2290. 被引量：1
7Kim S J, Kim J, Cho Y, et al. bortezomib, cyclophosphamide Combination chemotherapy with and dexamethasone may be effective for plasma cell leukemia[J]. Jpn J Clin Oncol, 2007, May 303 Epub ahead of print. 被引量：1
8Yan H, Wang Y C, Li D, et al, Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta[J]. Leukemia, 2007, 21 (7) : 1488-1495. 被引量：1
9Faderl S, Rai K, Gribben J, et al. Phase Ⅱ study of single-agent bortezomib for the treatment of patients with fludarabine- refractory B-cell chronic lymphocytic leukemia[J]. Cancer, 2006, 107(5) : 916-924. 被引量：1
8Julian Adams, Mark Behnke, Shaowu Chen, et al .Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids[J] .Bioorg Med Chem Lett, 1998, 8 (4) : 333. 被引量：1
9Friedberg JW, Cohen P, Chen L, et al. Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study [J]. J Clin Oncol, 2008, 26(2):204-210. 被引量：1
10Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma [J] . J Clin Oncol. 2005, 23(15):3383-3389. 被引量：1
